Evidence map›Paper›PMID 40449803›Full record

ArticleJournal of controlled release : official journal of the Controlled Release Society2025

COG133 peptide-conjugated lipid nanoparticles sensitize medulloblastoma to radiation therapy in mice.

Aditya Gupta, Sohan Mahto, Rebecca E Oberley Deegan, Donald W Coulter, Ram I Mahato

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of controlled release : official journal of the Controlled Release Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Lipid nanomedicine simultaneously inhibits BRD4/PI3K and MDM2/XIAP signaling pathways for effective treatment of Medulloblastoma.Journal of controlled release : official journal of the Controlled Release Society · 2025
    Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Aditya GuptaDepartment of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Sohan MahtoDepartment of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Rebecca E Oberley DeeganDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Donald W CoulterDepartment of Pediatrics, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Ram I MahatoDepartment of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE 68198, USA. Electronic address: ram.mahato@unmc.edu.

Funding

Lipid nanomedicine targeting multiple signaling pathways of medulloblastomaR01NS128336 · NINDS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI Ram I. Mahato · 2022 to 2026
$2.4M
Overcoming Resistance Mechanisms in Hedgehog and Myc-amplified MedulloblastomaR01NS116037 · NINDS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI COULTER, DONALD, MAHATO, RAM I. · 2021 to 2025
$1.9M
NINDS NIH HHS R01 NS116037NINDS NIH HHS R01 NS128336
6 · The paper itself

Abstract

Medulloblastoma (MB) is a malignant brain tumor that often arises in the cerebellum and has a propensity for spreading to the spinal cord or other parts of the central nervous system (CNS). Craniospinal irradiation (CSI) has long been a cornerstone in the treatment of MB, especially for patients with high-risk or metastatic disease. However, CSI often leads to long-term neurocognitive deficits, including learning disabilities, and growth abnormalities, especially in children. In this study, we aimed to decrease the dose of irradiation and the proliferation of MB by using Volasertib (VSB), a Polo-like kinase 1 (PLK1) specific inhibitor. VSB was highly potent in-vitro with an IC

Indexed as

Cerebellar NeoplasmsMedulloblastomaNanoparticlesPteridinesRadiation-Sensitizing AgentsAnimalsCell Cycle ProteinsCell Line, TumorFemaleHumansLipidsLiposomesMiceMice, NudePolo-Like Kinase 1Protein Serine-Threonine KinasesCell Cycle ProteinsLipid NanoparticlesLipidsLiposomesPolo-Like Kinase 1Protein Serine-Threonine KinasesProto-Oncogene ProteinsPteridinesRadiation-Sensitizing AgentsApoE mimetic peptideLipid nanoparticlesMedulloblastomaPLK1 inhibitorRadiation therapyVolasertib

Identifiers

PMID40449803
PMCPMC12794628

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.